The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma

The long-term efficacy of anti-angiogenesis drugs targeting vascular endothelial growth factor (VEGF) and VEGF receptors in the treatment of renal cell carcinoma (RCC) has been lacking. We have shown that the ELR(+)CXCL cytokines and their (C-X-C) chemokine receptors, namely CXCR1 and CXCR2, stimula...

Descripción completa

Detalles Bibliográficos
Autores principales: Giuliano, Sandy, Guyot, Mélanie, Grépin, Renaud, Pagès, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063157/
https://www.ncbi.nlm.nih.gov/pubmed/25050209
http://dx.doi.org/10.4161/onci.28399
Descripción
Sumario:The long-term efficacy of anti-angiogenesis drugs targeting vascular endothelial growth factor (VEGF) and VEGF receptors in the treatment of renal cell carcinoma (RCC) has been lacking. We have shown that the ELR(+)CXCL cytokines and their (C-X-C) chemokine receptors, namely CXCR1 and CXCR2, stimulate cancer cell proliferation, tumor inflammation, and angiogenesis. Hence, this essential molecular nexus regulating cancer growth represents a key therapeutic target.

Ejemplares similares